Literature DB >> 18172135

Characteristics of recipients of free prescription drug samples: a nationally representative analysis.

Sarah L Cutrona1, Steffie Woolhandler, Karen E Lasser, David H Bor, Danny McCormick, David U Himmelstein.   

Abstract

OBJECTIVES: Free prescription drug samples are used widely in the United States. We sought to examine characteristics of free drug sample recipients nationwide.
METHODS: We analyzed data on 32681 US residents from the 2003 Medical Expenditure Panel Survey (MEPS), a nationally representative survey.
RESULTS: In 2003, 12% of Americans received at least 1 free sample. A higher proportion of persons who had continuous health insurance received a free sample (12.9%) than did persons who were uninsured for part or all of the year (9.9%; P<.001). The poorest third of respondents were less likely to receive free samples than were those with incomes at 400% of the federal poverty level or higher. After we controlled for demographic factors, we found that neither insurance status nor income were predictors of the receipt of drug samples. Persons who were uninsured all or part of the year were no more likely to receive free samples (odds ratio [OR]=0.98; 95% confidence interval [CI]=0.087, 1.11) than those who were continuously insured.
CONCLUSIONS: Poor and uninsured Americans are less likely than wealthy or insured Americans to receive free drug samples. Our findings suggest that free drug samples serve as a marketing tool, not as a safety net.

Entities:  

Mesh:

Year:  2008        PMID: 18172135      PMCID: PMC2376889          DOI: 10.2105/AJPH.2007.114249

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  23 in total

1.  Hospital bans free drug samples.

Authors:  F Charatan
Journal:  West J Med       Date:  2001-04

2.  Medication sample labeling practices.

Authors:  J L Dill; J A Generali
Journal:  Am J Health Syst Pharm       Date:  2000-11-15       Impact factor: 2.637

3.  The value of pharmaceutical representative visits and medication samples in community-based family practices.

Authors:  E L Backer; J A Lebsack; R J Van Tonder; B F Crabtree
Journal:  J Fam Pract       Date:  2000-09       Impact factor: 0.493

4.  Promotion of prescription drugs to consumers.

Authors:  Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

5.  Effect of antihypertensive samples on physician prescribing patterns.

Authors:  John M Boltri; Elizabeth R Gordon; Robert L Vogel
Journal:  Fam Med       Date:  2002 Nov-Dec       Impact factor: 1.756

6.  A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998.

Authors:  Jun Ma; Randall S Stafford; Iain M Cockburn; Stan N Finkelstein
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

7.  Disposition of pharmaceutical samples from a private medical clinic.

Authors:  Michael C Peterson; Todd L Ebbert; Mike W Edwards; James Willmore
Journal:  J Am Pharm Assoc (2003)       Date:  2004 May-Jun

8.  Prescription drugs: elderly enrollee reports of financial access, receipt of free samples, and discussion of generic equivalents related to type of coverage.

Authors:  Deborah A Taira; Kimberly A Iwane; Richard S Chung
Journal:  Am J Manag Care       Date:  2003-04       Impact factor: 2.229

9.  A physician survey of the effect of drug sample availability on physicians' behavior.

Authors:  L D Chew; T S O'Young; T K Hazlet; K A Bradley; C Maynard; D S Lessler
Journal:  J Gen Intern Med       Date:  2000-07       Impact factor: 5.128

10.  Insurance status and patient behavior with asthma medications.

Authors:  Damien Stevens; Kailash Sharma; Steven Kesten
Journal:  J Asthma       Date:  2003       Impact factor: 2.515

View more
  24 in total

1.  Effect of drug sample removal on prescribing in a family practice clinic.

Authors:  Daniel M Hartung; David Evans; Dean G Haxby; Dale F Kraemer; Gabriel Andeen; Lyle J Fagnan
Journal:  Ann Fam Med       Date:  2010 Sep-Oct       Impact factor: 5.166

2.  Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.

Authors:  Walid F Gellad; Haiden A Huskamp; Angela Li; Yuting Zhang; Dana Gelb Safran; Julie M Donohue
Journal:  J Gen Intern Med       Date:  2011-07-13       Impact factor: 5.128

3.  "Free" prescription drug samples are not free.

Authors:  William R Vincent; Ann M Wiesner; Douglas T Steinke
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

4.  Evidence of sample use among new users of statins: implications for pharmacoepidemiology.

Authors:  Xiaojuan Li; Til Stürmer; M Alan Brookhart
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

5.  Infused chemotherapy use in the elderly after patent expiration.

Authors:  Rena M Conti; Meredith B Rosenthal; Blase N Polite; Peter B Bach; Ya-Chen Tina Shih
Journal:  J Oncol Pract       Date:  2012-05       Impact factor: 3.840

6.  Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.

Authors:  Jeanne M Madden; Alyce S Adams; Robert F LeCates; Dennis Ross-Degnan; Fang Zhang; Haiden A Huskamp; Daniel M Gilden; Stephen B Soumerai
Journal:  JAMA Psychiatry       Date:  2015-02       Impact factor: 21.596

7.  Free drug samples in the United States: characteristics of pediatric recipients and safety concerns.

Authors:  Sarah L Cutrona; Steffie Woolhandler; Karen E Lasser; David H Bor; David U Himmelstein; William H Shrank; Neal S LeLeiko
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

8.  Drug samples in dermatology: out of the closet, into the dustbin.

Authors:  Kenneth A Katz; Erika E Reid; Mary-Margaret Chren
Journal:  JAMA Dermatol       Date:  2014-05       Impact factor: 10.282

9.  Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea.

Authors:  Michael P Hurley; Randall S Stafford; Alfred T Lane
Journal:  JAMA Dermatol       Date:  2014-05       Impact factor: 10.282

10.  Prescribers and pharmaceutical representatives: why are we still meeting?

Authors:  Melissa A Fischer; Mary Ellen Keough; Joann L Baril; Laura Saccoccio; Kathleen M Mazor; Elissa Ladd; Ann Von Worley; Jerry H Gurwitz
Journal:  J Gen Intern Med       Date:  2009-05-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.